// App-Quantinova.ai

TPS4694 : A phase I/IIa study of the safety and efficacy of radium-223 chloride (Ra-223) with docetaxel (D) for castration-resistant prostate cancer (CRPC) patients with bone metastases.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Hans J. Hammers

  • Christopher Sweeney

  • Marianne Bloma

  • Anne-Kirsti Aksnes

  • C. Gillies O'Bryan-Tear

  • Jorge A. Carrasquillo

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Algeta ASA, Oslo, Norway

  • Dana-Farber Cancer Institute, Boston, MA

  • Johns Hopkins University, Baltimore, MD

Locations

  • United States

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Bone metastases

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Xofigo

  • Docetaxel

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved